Close Menu

Precision Oncology News: Breaking News

By identifying these biomarkers, the partners hope to better predict which SMM patients will progress to multiple myeloma and ultimately develop new treatments.

Janssen's biologics license application for amivantamab is the first regulatory submission for a drug to target lung cancer patients with EGFR exon 20 mutations.

Artios can receive $30 million in up-front and near-term payments, and up to $860 million per target if Merck KGaA exercises its exclusive development rights.

The lab's involvement will increase opportunities for cancer patients in these rural states to enroll in the trial and access molecularly informed treatments.

The company received permission from regulators in China to study the agent APG-115 in T-PLL, a rare leukemia characterized by an ATM mutation in most cases.

The company has begun a Phase III trial of infigratinib as a first-line treatment for FGFR2 fusion-positive cholangiocarcinoma.

The Phase I/II clinical trial will evaluate Genprex's Reqorsa and AstraZeneca's Tagrisso in patients with EGFR-mutated non-small cell lung cancer.

Chinese regulators have given LianBio permission to begin a Phase IIa trial of infigratinib in patients with gastric cancers harboring FGFR2 gene amplifications.

The combined company will focus on Viracta's precision oncology pipeline and lead product candidate for Epstein-Barr virus-positive cancers.

The trial will evaluate VS-6766 as a monotherapy or together with defactinib in ovarian cancer patients, including those with KRAS mutations.

Blood samples

The test uses a targeted methylation sequencing panel to detect more than 50 cancer types across all stages and pinpoint a cancer's tissue of origin.

The GD2-directed treatment had varying degrees of activity in a small Phase I study, though further improvements are needed to achieve durable responses.

A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.

The Phase I/II trial of PC14586 will involve patients with advanced solid tumors characterized by the p53 Y220C mutation.

The firm will collect stool and blood samples from 4,000 cancer patients and determine whether their microbiome composition affects their response to therapy.

The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations. 

The partnership goes hand-in-hand with Genentech's new precision basket trial, for which it will identify and enroll patients across OneOncology's network.

The regulatory submission triggers a milestone payment, and Invitae will issue 5 million shares of its common stock to former ArcherDx securityholders.

Through the partnership, Newsoara will develop and commercialize up to six targeted agents in greater China, while AUM will retain rights to the agents.

The trial is evaluating BP1002 to treat lymphoma and chronic lymphocytic leukemia patients whose tumors overexpress the protein BCL-2.

The UK-based firm will use the funds to advance its bespoke neoantigen-targeting T-cell therapies for solid cancers including melanoma and NSCLC.

Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.

The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.

The Swedish company will use the funds to grow its pipeline of antibodies to treat metastatic cancer and other diseases with the help of its Abiprot platform.

The funding will be used to complete enrollment for a Phase II study evaluating Elevation's lead product candidate seribantumab.